U.S. Markets open in 2 hrs 20 mins

CLASS ACTION UPDATE for MMM, KPTI and IFF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / September 23, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

3M Company (MMM)

Lawsuit on behalf of: investors who purchased February 9, 2017 - May 28, 2019
Lead Plaintiff Deadline : September 27, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/3m-company-loss-form?prid=3641&wire=1

According to the filed complaint, during the class period, 3M Company made materially false and/or misleading statements and/or failed to disclose that: (i) 3M had vast internal evidence dating back decades confirming that polyfluoroalkyl substances ("PFAS") are toxic (which was first publicly revealed in February 2018 by Minnesota's Attorney General); (ii) 3M had a decades-long history of suppressing negative information and/or damaging data about PFAS; and (iii) 3M has legal exposure to state, county, and local governments and individuals around the country as a result of its knowledge and intentional concealment of the toxic harm caused by the use of PFAS.

Karyopharm Therapeutics Inc (KPTI)

Lawsuit on behalf of: investors who purchased on behalf of shareholders who: (i) purchased shares of Karyopharm's securities between March 2, 2017 and February 22, 2019, inclusive (ii) purchased Karyopharm shares in or traceable to the Company's public offering of common stock conducted on or around April 28, 2017; or (iii) purchased Karyopharm shares in or traceable to the Company's public offering of common stock conducted on or around May 7, 2018.
Lead Plaintiff Deadline : September 23, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/karyopharm-therapeutics-inc-loss-form?prid=3641&wire=1

According to the filed complaint, Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a "predictable and manageable tolerability profile" and a "very nice safety profile," and assured investors that it was "well tolerated" by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.

International Flavors & Fragrances Inc. (IFF)

Lawsuit on behalf of: investors who purchased May 7, 2018 - August 5, 2019
Lead Plaintiff Deadline : October 11, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/international-flavors-fragrances-inc-loss-form?prid=3641&wire=1

According to the filed complaint, during the class period, International Flavors & Fragrances Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) that Frutarom Industries Ltd. ("Frutarom"), which the Company acquired in 2018, had bribed customers in Russia and Ukraine; (2) that senior management at Frutarom were aware of such improper payments; (3) that, as a result, Frutarom's financial results were materially overstated; (4) that, as a result of the improper payments, the Company was reasonably likely to face regulatory scrutiny; (5) that the Company had not completed adequate due diligence before acquiring Frutarom; (6) that, as a result of the foregoing, the Company was unlikely to achieve purported synergies from the acquisition; and (7) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/560661/CLASS-ACTION-UPDATE-for-MMM-KPTI-and-IFF-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders